The 47th Annual San Antonio Breast Cancer Symposium features research from authors affiliated with the University of Illinois Cancer Center, the University of Illinois Chicago (UIC) and UI Health. The 2024 symposium takes place December 10 – 13.
A listing of their featured research is below. All symposium abstracts are available here.
The symposium, co-sponsored by the UT Health San Antonio Mays Cancer Center and the American Association for Cancer Research (AACR), includes more than 10,000 registered attendees from 102 countries.
Mainstream Cancer Genetics Testing in Primary Care at a Federally Qualified Health Center: Preliminary Findings from the TestMiGenes Study
Presenting Author(s): Pamela Ganschow, MD and Co-Author(s): Vivian Pan, MS, CGC, Angelina Izguerra, BPH, Genesis Rios, MPH, Neha Awati, MD
Use of a Digital Navigator to Deliver Patient-Centered Genetic Services in Mammography
Presenting Author(s): Tara Schmidlen, MS and Co-Author(s): Emilie Simmons, MS, Vivian Pan, MS, CGC, Neha Awati, MD, Lara Balay, MS Ed, MS, CGC, Iris Fietko, BS, Angelina Izguera, BPH, Genesis Rios, MPH, Moran Snir, MS, MBA, Pamela Ganschow, MD
Impact of Estrogen Receptor Targeting Drugs on a Novel Epithelial-Mesenchymal Transition Pathway in Endocrine Resistant Breast Cancer: Implications for Metastasis
Presenting Author(s): Nivida Shete and Co-Author(s): Debra A. Tonetti, PhD
Correlation Between Risk Groups and Molecular Subtype of Breast Cancer with Metabolic Syndrome and Ethnicity
Presenting Author(s): Sharda P. Singh and Co-Author(s): Sharda P. Singh, Chathurika
Samudani Dhanasekara, Michael W. Melkus, Reshad S. Ghafouri, Soroush Shahrokh, Flavia
Sardela de Miranda, Maria F. Mahecha, Adam Brufsky, Joyce O’Shaugnessy, VK Gadi, Cathy
Graham, Mehran Habibi, William Audeh, Sahra Uygun, Lavanya Samraj, Rakhshanda
Layeequr Rahman
Tolerability of First-Line (1L) Treatment (tx) With Ribociclib (RIB) for Metastatic Breast Cancer (MBC) Using 2 Large US Data Sources
Presenting Author(s): Sarah L. Sammons and Co-Author(s): Priyanka Sharma, Yara Abdou,
VK Gadi, Taavy A. Miller, Spencer S. Langerman, Dominick Latremouille-Viau, Annie Guerin,
Carmine Rossi, Emily McGovern, Gary Sopher, Vamsi Bollu, Natalia Bolotova, Şerban R.
Iorga, Liz Santarsiero, Susan Dent
Alpelisib (BYL719) with Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor–Positive, HER2-Negative, PIK3CA-Mutant Metastatic Breast Cancer: A Big Ten Cancer Research Consortium Study
Presenting Author(s): Darian Louthan and Co-Author(s): Marina N Sharifi, Oana C. Danciu,
Jairam Krishnamurthy, Monali K. Vasekar, Kent Hoskins, Michael Lasarev, Jens Eikhoff, Ruth
M. O’Regan, Kari B. Wisinski, Cristina I. Truica
Prediction of Chemotherapy Benefit by MammaPrint® in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data
Presenting Author(s): Adam Brufsky and Co-Author(s): Adam Brufsky, Kent Hoskins, Henry
Conter, Pond Kelemen, Mehran Habibi, Laila Samian, Robert Maganini, Rakshanda Rahman,
Laura Lee, Eduardo Dias, Regina Hampton, Beth Seiling, Cynthia Osborne, Eric Brown, Jailan
Elayoubi, Priyanka Sharma, Jayanthi Ramadurai, Laurie Matt-Amral, Alfredo Santillan, Sasha
Strain, Philip Albaneze, Harshini Ramaswamy, Nicole Stivers, Andrea Menicucci, William
Audeh, Pat Whitworth, Nathalie Johnson, Joyce O’Shaughnessy
FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients with Early-Stage Breast Cancer
Presenting Author(s): Robert Maganini and Co-Author(s): Ellis Levine, Kent Hoskins, Sarah
Thayer, Alfredo Santillan, Sung Ho-Lee, Eduardo Dias, Regina Hampton, Eric Brown,
Maxwell Brown, Joyce O’ Shaughnessy, Nicole Stivers, Harshini Ramaswamy, Katie Quinn,
Isha Kapoor, William Audeh
Single-Cell and Spatial Approach to Study Endocrine Therapy Sensitivity in Breast Cancer Models with Heterogeneous Estrogen Receptor Expression
Presenting Author(s): Svetlana Semina and Co-Author(s): Rosemary J. Huggins, Huiping
Zhao, Debra Tonetti, Kent Hoskins, Geoffrey L. Greene, Jonna Frasor